24/7 Market News Snapshot 10 September, 2025 – PMV Pharmaceuticals, Inc (NASDAQ:PMVP)

September 10, 2025

DENVER, Colo., 10 September, 2025 (www.247marketnews.com) – (NASDAQ:PMVP) are discussed in this article.
PMV Pharmaceuticals, Inc. has experienced a substantial increase in its stock price, trading at $2.50 during pre-market hours, marking a significant gain of 56.37% from the previous day’s close of $1.60. The surge, accompanied by a trading volume of 3.25 million shares, signals heightened investor interest and positive market sentiment regarding the company’s recent developments.

Key to this optimism is PMV’s announcement of interim data from the Phase 2 pivotal segment of its ongoing PYNNACLE clinical trial. This trial assesses the efficacy of rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation. The interim analysis revealed a noteworthy overall response rate (ORR) of 33% across a variety of tumor types, including ovarian, lung, breast, and endometrial cancers, from a cohort of 97 evaluable patients. Notably, the ovarian cancer subgroup showed an even stronger ORR of 43%, with the median duration of response recorded at 7.6 months.

The trial has thus far illustrated an encouraging safety profile, with the majority of treatment-related adverse events categorized as Grade 1-2. Moreover, improved gastrointestinal tolerability was observed when rezatapopt was taken with food, enhancing the treatment experience for affected patients.

Building on these positive results, PMV Pharmaceuticals is set to submit a New Drug Application (NDA) for rezatapopt aimed at treating platinum-resistant/refractory ovarian cancer by the first quarter of 2027, with expectations for additional patient enrollment by early 2026.

Dr. Deepika Jalota, Chief Development Officer, remarked, “Today’s data reinforces our commitment to advance innovative therapies that address significant unmet needs among cancer patients.” The company is poised to provide further insights into these interim results through an upcoming investor webinar, highlighting its dedication to transforming cancer treatment through pioneering p53-targeted therapies.

Related news for (PMVP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.